Table 1 Patient demographics used for propensity score matching in the matched comparison groups
Comparison 1 | Comparison 2 | Comparison 3 | ||||
|---|---|---|---|---|---|---|
G-CSF + plerixafor (N = 77) | G-CSF alone (N = 41) | G-CSF + plerixafor (N = 129) | G-CSF + chemo (N = 129) | G-CSF + plerixafor + chemo (N = 117) | G-CSF + chemo (N = 117) | |
Age at diagnosis, mean years ± standard deviation | 57.5 ± 8.4 | 56.1 ± 8.1 | 58.2 ± 7.8 | 58.6 ± 7.0 | 60.0 ± 7.5 | 59.6 ± 7.1 |
Age at first mobilization, mean years ± standard deviation | 58.2 ± 8.4 | 57.0 ± 8.4 | 59.3 ± 7.8 | 59.5 ± 6.8 | 61.3 ± 6.9 | 60.6 ± 6.8 |
Female sex, n (%) | 37 (48.1) | 21 (51.2) | 43 (33.3) | 42 (32.6) | 55 (47.0) | 59 (50.4) |
Bone marrow involvement at the start of mobilization, n/N (%) | 9/55 (16.4) | 4/31 (12.9) | 32/95 (33.7) | 37/108 (34.3) | 43/93 (46.2) | 35/99 (35.4) |
Status of disease at collection, n (%) | N = 60 | N = 37 | N = 102 | N = 100 | N = 87 | N = 89 |
Complete response or stringent complete response | 8 (13.3) | 6 (16.2) | 13 (12.7) | 10 (10.0) | 5 (5.7) | 6 (6.7) |
Partial response | 44 (73.3) | 26 (70.3) | 73 (71.6) | 80 (80.0) | 77 (88.5) | 81 (91.0) |
Stable disease | 6 (10.0) | 4 (10.8) | 8 (7.8) | 7 (7.0) | 3 (3.4) | 1 (1.1) |
Progressive disease | 2 (3.3) | 1 (2.7) | 8 (7.8) | 3 (3.0) | 2 (2.3) | 1 (1.1) |
Durie and Salmon disease stage at diagnosis, n (%) | N = 68 | N = 40 | N = 115 | N = 115 | N = 91 | N = 105 |
A-1 | 2 (2.9) | 3 (7.5) | 8 (7.0) | 8 (7.0) | 11 (12.1) | 8 (7.6) |
A-II | 8 (11.8) | 7 (17.5) | 15 (13.0) | 24 (20.9) | 17 (18.7) | 24 (22.9) |
A-III | 43 (63.2) | 23 (57.5) | 68 (59.1) | 64 (55.7) | 53 (58.2) | 63 (60.0) |
B-I | 0.0 | 0.0 | 2 (1.7) | 0.0 | 0.0 | 0.0 |
B-II | 3 (4.4) | 0.0 | 5 (4.3) | 1 (0.9) | 0.0 | 0.0 |
B-III | 12 (17.6) | 7 (17.5) | 17 (14.8) | 18 (15.7) | 10 (11.0) | 10 (9.5) |
Interval between diagnosis and first collection, mean months ± SD | 9.2 ± 10.8 | 10.7 ± 10.6 | 13.0 ± 19.8 | 10.0 ± 21.0 | 14.1 ± 36.5 | 11.1 ± 22.3 |
Multiple graft programme, n (%) | ||||||
Yes | 1 (1.3) | 1 (2.6) | 1 (0.8) | 4 (3.1) | 8 (6.8) | 13 (11.1) |
No | 75 (98.7) | 38 (97.4) | 127 (99.2) | 124 (96.9) | 109 (93.2) | 104 (88.9) |
Year of first transplant | ||||||
2008 | 8 (10.4) | 13 (31.7) | 8 (6.2) | 8 (6.2) | 5 (4.3) | 9 (7.7) |
2009 | 20 (26.0) | 8 (19.5) | 32 (24.8) | 35 (27.1) | 13 (11.1) | 17 (14.5) |
2010 | 20 (26.0) | 11 (26.8) | 24 (18.6) | 28 (21.7) | 31 (26.5) | 40 (34.2) |
2011 | 18 (23.4) | 6 (14.6) | 32 (24.8) | 33 (25.6) | 30 (25.6) | 29 (24.8) |
2012 | 11 (14.3) | 3 (7.3) | 33 (25.6) | 25 (19.4) | 38 (32.5) | 22 (18.8) |
Geographic region | ||||||
South and East Europe | 18 (23.4) | 11 (26.8) | 32 (24.8) | 30 (23.3) | 34 (29.1) | 37 (31.6) |
North and West Europe | 59 (76.6) | 30 (73.2) | 97 (75.2) | 99 (76.7) | 83 (70.9) | 80 (68.4) |
Multiple myeloma disease types, n (%) | ||||||
IgG | 42 (54.5) | 22 (53.7) | 78 (60.5) | 81 (62.8) | 63 (53.8) | 65 (55.6) |
IgA | 12 (15.6) | 8 (19.5) | 16 (12.4) | 17 (13.2) | 32 (27.4) | 30 (25.6) |
Light chain (kappa and lambda) | 20 (26.0) | 9 (22.0) | 32 (24.8) | 28 (21.7) | 15 (12.8) | 17 (14.5) |
IgD, IgE, or IgM | 2 (2.6) | 1 (2.4) | 2 (1.6) | 3 (2.3) | 6 (5.1) | 3 (2.6) |
Nonsecretory | 1 (1.3) | 1 (2.4) | 1 (0.8) | 0.0 | 1 (0.9) | 2 (1.7) |
